Ohcanbohtosat - Jason D. Lickliter

First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects Dahkki Jing Yang, Jason D. Lickliter, Jan L. Hillson, Gary D. Means, Russell J. Sanderson, Kay Carley, Almudena Tercero, Kristi L. Manjarrez, Jennifer R. Wiley, Stanford L. Peng

Connect to this object online.